Mersana Therapeutics (MRSN) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Mersana (MRSN) PT Raised to $15 at Citi, Opens Catalyst Watch
May 10, 2023 3:24 PM EDTCiti analyst Ashiq Mubarack raised the price target on Mersana (NASDAQ: MRSN) to $15.00 (from $12.00) while maintaining a Buy rating.
The analys topens a 90-day upside catalyst watch commenting "In mid-2023, MRSN will share topline results from the pivotal UPLIFT Ph2 trial evaluating UpRi in... More
